Bmab 1100 (Pegfilgrastim biosimilar)
Chemotherapy-induced Neutropenia
Key Facts
About Biocon
Biocon's mission is to deliver affordable, high-quality biopharmaceuticals to a global patient population. The company has achieved global leadership in biosimilars, with multiple commercialized products in oncology, immunology, and diabetes, and has built a fully integrated platform from R&D to manufacturing. Its strategy is anchored in leveraging its deep bioprocessing expertise to expand its biosimilar portfolio, advance a pipeline of novel biologics, and grow its contract research and manufacturing services.
View full company profileTherapeutic Areas
Other Chemotherapy-induced Neutropenia Drugs
| Drug | Company | Phase |
|---|---|---|
| BBT-015 | Bolder Biotechnology | Preclinical |
| Ziextenzo (pegfilgrastim) | Sandoz Group | Marketed |
| Biosimilar Pegfilgrastim | Viatris | Launched |
| UDENYCA (pegfilgrastim-cbqv) | Coherus BioSciences | Approved |
| ROLVEDON | Assertio Holdings | Approved |